Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK2 | O96017 | 3/20 | 0.71 |
| ▸ | FYN | P06241 | 7/20 | 0.67 |
| ▸ | MAP4K4 | O95819 | 6/20 | 0.65 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.57 |
| ▸ | NEK1 | Q96PY6 | 1/20 | 0.54 |
| ▸ | SRC | P12931 | 1/20 | 0.54 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.53 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1679484 | 0.82 | CHEK2 (0.60) | CHEK2FYNMAP4K4CHEK1NEK1 | |
| SCHEMBL4254012 | 0.82 | STIM1 (0.62) | — | |
| SCHEMBL1679706 | 0.81 | PRKD3 (0.75) | CHEK2FYNMAP4K4CHEK1 | |
| SCHEMBL4620276 | 0.80 | FYN (1.00) | CHEK2FYNMAP4K4CHEK1TGFBR1 | |
| SCHEMBL30521818 | 0.80 | FYN (1.00) | CHEK2FYNMAP4K4CHEK1TGFBR1 | |
| SCHEMBL5118154 | 0.80 | CHEK2 (0.57) | CHEK2FYNMAP4K4CHEK1SRC | |
| SCHEMBL1679734 | 0.79 | CHEK2 (0.56) | CHEK2FYNCHEK1NEK1TGFBR1 | |
| SCHEMBL1679485 | 0.79 | PRKD3 (0.65) | CHEK2FYNCHEK1NEK1 | |
| SCHEMBL30521781 | 0.79 | FYN (1.00) | CHEK2FYNCHEK1TGFBR1 | |
| SCHEMBL18613463 | 0.79 | FYN (1.00) | CHEK2FYNCHEK1TGFBR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110098325-A1 | PYRIDINE BENZAMIDES AND PYRAZINE BENZAMIDES USED AS PKD INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2011-04-28 | — | — | US | disclosed |
| US-20110098325-A1 | PYRIDINE BENZAMIDES AND PYRAZINE BENZAMIDES USED AS PKD INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2011-04-28 | — | — | US | disclosed |
| US-20110098325-A1 | PYRIDINE BENZAMIDES AND PYRAZINE BENZAMIDES USED AS PKD INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2011-04-28 | — | — | US | disclosed |
| EP-2114887-A1 | PYRIDINE BENZAMIDES AND PYRAZINE BENZAMIDES USED AS PKD INHIBITORS | Cancer Research Technology Limited (GB) | 2009-11-11 | — | — | EP | disclosed |
| WO-2008074997-A1 | PYRIDINE BENZAMIDES AND PYRAZINE BENZAMIDES USED AS PKD INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2008-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098325-A1 | PYRIDINE BENZAMIDES AND PYRAZINE BENZAMIDES USED AS PKD INHIBITORS | PKD2, PKD1, BAZ2B | CHEK2 587/4885FYN 1665/4885MAP4K4 31/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.